Jacob, Stephan

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 3,163

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial

Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,829

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 638

Effects of Intravenous and Dietary Lipid Challenge on Intramyocellular Lipid Content and the Relation With Insulin Sensitivity in Humans

Bachmann, O. P., Dahl, D. B., Brechtel, K., Machann, J., Haap, M., Maier, T., Loviscach, M., Stumvoll, M., Claussen, C. D., Schick, F., et al. (2001) · Diabetes

Diabetes, Cardiovascular Risks, and LipoproteinsDiet, Metabolism, and Disease

Cited by 369

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity

Wharton, S., Lingvay, I., Bogdanski, P., Duque do Vale, R., Jacob, S., Karlsson, T., Shaji, C., Rubino, D., & Garvey, W. T. (2025) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 142

Cardiovascular outcome trials in obesity: A review

Wilding, J. P. H., & Jacob, S. (2021) · Obesity Reviews

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 75

Lipid content in the musculature of the lower leg assessed by fat selective MRI: Intra‐ and interindividual differences and correlation with anthropometric and metabolic data

Machann, J., Bachmann, O. P., Brechtel, K., Dahl, D. B., Wietek, B., Klumpp, B., Häring, H., Claussen, C. D., Jacob, S., & Schick, F. (2003) · Journal of Magnetic Resonance Imaging

Advanced MRI Techniques and ApplicationsBody Composition Measurement Techniques

Cited by 73

Suppression of Systemic, Intramuscular, and Subcutaneous Adipose Tissue Lipolysis by Insulin in Humans 1

Stumvoll, M., Jacob, S., Wahl, H. G., Hauer, B., Löblein, K., Grauer, P., Becker, R., Nielsen, M., Renn, W., & Häring, H. (2000) · The Journal of Clinical Endocrinology & Metabolism

Lipid metabolism and biosynthesisAdipose Tissue and Metabolism

Cited by 63

Body weight management and safety with efpeglenatide in adults without diabetes: a phase II randomized study

Pratley, R. E., Kang, J., Trautmann, M. E., Hompesch, M., Han, O., Stewart, J., Sorli, C. H., Jacob, S., & Yoon, K. (2019) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 49

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany

Menzen, M., Berentzen, T. L., Catarig, A.-M., Pieperhoff, S., Simon, J., & Jacob, S. (2023) · Experimental and Clinical Endocrinology & Diabetes

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 29

Usability Evaluation of a Blood Glucose Monitoring System With a Spill-Resistant Vial, Easier Strip Handling, and Connectivity to a Mobile App: Improvement of Patient Convenience and Satisfaction

Harvey, C., Koubek, R., Bégat, V., & Jacob, S. (2016) · Journal of Diabetes Science and Technology

Usability and User Interface DesignDiabetes Management and Research

Cited by 19